WOBURN, Mass., July 7, 2025 /PRNewswire/ -- Sirtex Medical ("Sirtex"), a leading manufacturer of interventional oncology solutions, today announced that the U.S. Food and Drug Administration (FDA) ...
SIR-Spheres® Y-90 resin microspheres are now FDA-approved for unresectable HCC, marking a unique approval for both HCC and mCRC in the U.S. The DOORwaY90 study showed a 98.5% overall response rate and ...
Patients with advanced or inoperable Hepatocellular Carcinoma (HCC) who usually received one or two treatments with liver-directed SIR-Spheres Y-90 resin microspheres in the 459-patient French SARAH ...
According to investigators, the use of SIR-Spheres microspheres in elderly patients with unresectable colorectal liver metastases (mCRC) appears to be as effective and well-tolerated as in younger ...
Sirtex Medical (Sirtex), a leading manufacturer of interventional treatment solutions, announced the launch of its SIR-Spheres FLEXdose SELECT Delivery Programme, an innovative, new way to offer ...
Expanded indication makes SIR-Spheres® the first and only radioembolization therapy in the U.S. approved to treat both unresectable hepatocellular carcinoma and metastatic colorectal cancer WOBURN, ...
Sirtex Medical (Sirtex), a leading manufacturer of interventional oncology solutions, announced that the US Food and Drug Administration (FDA) approved SIR-Spheres Y-90 resin microspheres for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results